2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsFemaleGenes, BRCA1Genetic Predisposition to DiseaseGenetic TestingHumansInsurance, HealthMiddle AgedMutationConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyInitial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race